title: ECOG phase II trials of MGBG, chlorozotocin, COM multidrug therapy in advanced measurable colorectal cancer.
abstract: The Eastern Cooperative Oncology Group (ECOG) entered 326 patients with advanced measurable colorectal cancer into four phase II drug or drug combination trials. Previously treated and chemotherapy-naive patients were eligible. Chlorozotocin was administered to 83 patients (51 previously treated), methyl-glyoxal-bis-guanylhydrozone (MGBG) to 90 patients (58 previously treated), and two regimens of the three-drug combination of cyclophosphamide, vincristine, and methotrexate (COM) to 153 patients (120 previously treated). The multidrug regimen had been developed specifically for previously treated patients. In this trial, chemotherapy-naive patients were no more likely to respond than were members of the previously-treated group. Even among previously untreated patients, response rates did not exceed 10% in any of these phase II programs. They are not recommended for further trials in patients with colorectal cancers.
authors.affiliation: Roswell Park Memorial Institute, Buffalo, New York 14263.
authors.forename: H O
authors.initials: HO
authors.lastname: Douglass
authors.forename: M
authors.initials: M
authors.lastname: Lefkopoulou
authors.forename: H L
authors.initials: HL
authors.lastname: Davis
authors.forename: S G
authors.initials: SG
authors.lastname: Taylor
authors.forename: G
authors.initials: G
authors.lastname: Falkson
authors.forename: A
authors.initials: A
authors.lastname: Mittelman
authors.forename: J
authors.initials: J
authors.lastname: MacIntyre
authors.forename: P F
authors.initials: PF
authors.lastname: Engstrom
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004341:Drug Evaluation; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008935:Mitoguazone / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy*; D013311:Streptozocin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage
chemical_list: C007028:chlorozotocin; D014750:Vincristine; D013311:Streptozocin; D003520:Cyclophosphamide; D008935:Mitoguazone; D008727:Methotrexate